AN 9

Drug Profile

AN 9

Alternative Names: Pivaloyloxymethyl Butyrate; Pivanex

Latest Information Update: 26 Mar 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bar-Ilan University
  • Class Antineoplastics; Butyrates; Butyric acids
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Liver cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 18 Mar 2005 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV)
  • 18 Mar 2005 Discontinued - Phase-II for Malignant melanoma in USA (Topical)
  • 12 Jul 2004 AN 9 is available for licensing (http://www.titanpharm.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top